A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose
escalation and expansion study designed to determine the safety and tolerability of STM-416
in patients with bladder cancer.